CTOs on the Move

Aspect Biosystems

www.aspectbiosystems.com

 
Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company`s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aspect Biosystems raised $20M on 01/09/2020

Similar Companies

Provivi

We are a groundbreaking science-based company creating scalable, safer insect control technology that will improve the quality of life for all humans and our world.

United Biomedical

United Biomedical, Inc. (UBI) is an international bio/pharmaceutical firm with cutting edge technology utilizing reverse genomics and synthetic peptide chemistry, coupled with traditional pharmaceutical and therapeutic delivery systems. The company has

Sigma-Tau Pharmaceuticals

Sigma-Tau Pharmaceuticals is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Polar Electro Inc

Polar Electro Inc is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.